FR2714057B1
(fr)
*
|
1993-12-17 |
1996-03-08 |
Sanofi Elf |
Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
|
FR2741621B1
(fr)
*
|
1995-11-23 |
1998-02-13 |
Sanofi Sa |
Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
|
FR2742148B1
(fr)
*
|
1995-12-08 |
1999-10-22 |
Sanofi Sa |
Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
|
FR2758723B1
(fr)
*
|
1997-01-28 |
1999-04-23 |
Sanofi Sa |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
FR2761265B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
|
FR2761266B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
|
JP2002512188A
(ja)
|
1998-04-21 |
2002-04-23 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ レプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抗酸化剤及び神経保護剤としてのカンナビノイド類
|
JP3852644B2
(ja)
|
1998-09-21 |
2006-12-06 |
チッソ株式会社 |
分割型複合繊維、これを用いた不織布及び吸収性物品
|
FR2789079B3
(fr)
|
1999-02-01 |
2001-03-02 |
Sanofi Synthelabo |
Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
|
FR2799124B1
(fr)
|
1999-10-01 |
2004-08-13 |
Sanofi Synthelabo |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
US7393842B2
(en)
*
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
FR2800372B1
(fr)
*
|
1999-11-03 |
2001-12-07 |
Sanofi Synthelabo |
Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
|
FR2804604B1
(fr)
|
2000-02-09 |
2005-05-27 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
|
JP2004502642A
(ja)
*
|
2000-02-11 |
2004-01-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
|
FR2809621B1
(fr)
*
|
2000-05-12 |
2002-09-06 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
|
FR2814678B1
(fr)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
US8449908B2
(en)
|
2000-12-22 |
2013-05-28 |
Alltranz, Llc |
Transdermal delivery of cannabidiol
|
AU2002319627A1
(en)
|
2001-07-20 |
2003-03-03 |
Merck And Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
FR2831883B1
(fr)
*
|
2001-11-08 |
2004-07-23 |
Sanofi Synthelabo |
Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
SE0104330D0
(sv)
*
|
2001-12-19 |
2001-12-19 |
Astrazeneca Ab |
Therapeutic agents
|
AU2003215024B2
(en)
*
|
2002-03-26 |
2008-02-21 |
Merck Sharp & Dohme Corp. |
Spirocyclic amides as cannabinoid receptor modulators
|
FR2837706A1
(fr)
*
|
2002-03-28 |
2003-10-03 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
|
JP4459629B2
(ja)
*
|
2002-04-12 |
2010-04-28 |
メルク エンド カムパニー インコーポレーテッド |
二環式アミド
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
US7402835B2
(en)
*
|
2002-07-18 |
2008-07-22 |
Chevron U.S.A. Inc. |
Heteroatom-containing diamondoid transistors
|
CA2487849A1
(en)
|
2002-07-18 |
2004-01-29 |
Cytos Biotechnology Ag |
Hapten-carrier conjugates comprising virus like particles and uses thereof
|
EP1532132B1
(de)
|
2002-07-29 |
2008-03-19 |
F.Hoffmann-La Roche Ag |
Neue benzodioxole
|
JP2006510597A
(ja)
|
2002-09-27 |
2006-03-30 |
メルク エンド カムパニー インコーポレーテッド |
置換ピリミジン類
|
GB0228417D0
(en)
*
|
2002-12-05 |
2003-01-08 |
Cancer Rec Tech Ltd |
Pyrazole compounds
|
MXPA05007114A
(es)
|
2003-01-02 |
2005-08-26 |
Hoffmann La Roche |
Nuevos agonistas inversos del receptor cb1.
|
JP4271660B2
(ja)
|
2003-01-02 |
2009-06-03 |
エフ.ホフマン−ラ ロシュ アーゲー |
ピロリル−チアゾール及びcb1受容体逆作動物質としてのその使用
|
AR043633A1
(es)
*
|
2003-03-20 |
2005-08-03 |
Schering Corp |
Ligandos de receptores de canabinoides
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
GB0314049D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
WO2004111033A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Astrazeneca Ab |
2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
EP1638556B1
(de)
|
2003-06-20 |
2008-04-02 |
F. Hoffmann-La Roche Ag |
2-aminobenzothiazole als cb1 rezeptor inverse agonisten
|
GB0327331D0
(en)
*
|
2003-11-25 |
2003-12-31 |
Astrazeneca Ab |
Therapeutic agents
|
JP4527729B2
(ja)
|
2003-12-08 |
2010-08-18 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規チアゾール誘導体
|
FR2864958B1
(fr)
*
|
2004-01-12 |
2006-02-24 |
Sanofi Synthelabo |
Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
|
EP1574211A1
(de)
|
2004-03-09 |
2005-09-14 |
Inserm |
Verwendung von CB1-Rezeptor-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankungen
|
CA2564986A1
(en)
|
2004-05-10 |
2005-11-17 |
F. Hoffmann-La Roche Ag |
Pyrrole or imidazole amides for treating obesity
|
ITMI20041033A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
ITMI20041032A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
CN101014605A
(zh)
|
2004-07-12 |
2007-08-08 |
卡地拉健康护理有限公司 |
用作大麻素受体调节物的三环吡唑衍生物
|
FR2873372B1
(fr)
*
|
2004-07-22 |
2006-09-08 |
Sanofi Synthelabo |
Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
FR2874012B1
(fr)
*
|
2004-08-09 |
2008-08-22 |
Sanofi Synthelabo |
Derives de pyrrole, leur preparation et leur utlisation en therapeutique
|
KR100912146B1
(ko)
|
2004-10-27 |
2009-08-14 |
에프. 호프만-라 로슈 아게 |
인돌 또는 벤즈이미다졸 유도체
|
EP2286840A3
(de)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Behandlung von Fettleibigkeit und von verwandten Krankheiten
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP1812418B1
(de)
|
2004-11-09 |
2010-10-27 |
F. Hoffmann-La Roche AG |
Dibenzosuberon-derivate
|
RU2007122351A
(ru)
*
|
2004-11-15 |
2008-12-20 |
Тайсо Фармасьютикал Ко. |
Иминовое соединение
|
FR2880023B1
(fr)
|
2004-12-23 |
2007-02-23 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
|
EP1844017A1
(de)
*
|
2005-01-06 |
2007-10-17 |
Cadila Healthcare Ltd. |
Amorphe und drei kristalline formen von rimonabanthydrochlorid
|
JP2008526887A
(ja)
*
|
2005-01-10 |
2008-07-24 |
ユニバーシティ オブ コネチカット |
カンナビノイド受容体に作用する新規なヘテロピロール類似体
|
US8853205B2
(en)
|
2005-01-10 |
2014-10-07 |
University Of Connecticut |
Heteropyrrole analogs acting on cannabinoid receptors
|
FR2881744B1
(fr)
|
2005-02-09 |
2007-04-27 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
|
US20090286723A1
(en)
|
2005-02-11 |
2009-11-19 |
Amylin Pharmaceuticals, Inc. |
Hybrid Polypeptides with Selectable Properties
|
FR2882263B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
FR2882262B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
DE102005011050A1
(de)
|
2005-03-10 |
2006-09-21 |
Degussa Ag |
Verfahren zur Herstellung von 1-Aminopiperidinderivaten
|
WO2006106054A1
(en)
|
2005-04-06 |
2006-10-12 |
F. Hoffmann-La Roche Ag |
Pyridine-3-carboxamide derivatives as cb1 inverse agonists
|
CN1310891C
(zh)
*
|
2005-05-19 |
2007-04-18 |
金鑫 |
N-哌啶基-1-(2,4-二氯苯基)-4-甲基-5-(4-氯苯基)吡唑-3-甲酰胺有机酸盐及其药物组合物
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
CA2613235A1
(en)
|
2005-06-30 |
2007-01-11 |
Prosidion Limited |
Gpcr agonists
|
FR2888236B1
(fr)
*
|
2005-07-08 |
2007-09-21 |
Sanofi Aventis Sa |
Derives de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique
|
EP1743637A1
(de)
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
Verwendung substituierter Pyrazolinderivate und Kombinationen davon zur Behandlung des metabolischen Syndroms
|
GB0514739D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Astrazeneca Ab |
Therapeutic agents
|
EP1752149A1
(de)
|
2005-07-29 |
2007-02-14 |
Laboratorios Del Dr. Esteve, S.A. |
CB1 Antagonists oder umgekehrte Agonists als therapeutische Mittel zur Behandlung der Entzündung mit einbeziehenden Genausdruck
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
KR20080048502A
(ko)
|
2005-09-29 |
2008-06-02 |
머크 앤드 캄파니 인코포레이티드 |
멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
|
JP5069894B2
(ja)
*
|
2005-10-21 |
2012-11-07 |
田辺三菱製薬株式会社 |
ピラゾール化合物
|
CN100999517B
(zh)
*
|
2006-01-11 |
2010-12-15 |
北京摩力克科技有限公司 |
吡唑甲酰胺衍生物,药物组合物和其制备方法
|
EP1816125A1
(de)
*
|
2006-02-02 |
2007-08-08 |
Ranbaxy Laboratories, Ltd. |
Kristalline Formen eines CB1-Cannabinoidrezeptorantagonisten und deren Herstellungsverfahren
|
FR2897060B1
(fr)
*
|
2006-02-08 |
2008-07-25 |
Sanofi Aventis Sa |
Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
CN101062919B
(zh)
*
|
2006-04-26 |
2012-08-15 |
中国人民解放军军事医学科学院毒物药物研究所 |
4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
|
WO2007121687A1
(fr)
*
|
2006-04-26 |
2007-11-01 |
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China |
Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
|
FR2902008A1
(fr)
*
|
2006-06-07 |
2007-12-14 |
Sanofi Aventis Sa |
Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
WO2008038143A2
(en)
*
|
2006-06-22 |
2008-04-03 |
Medichem, S.A. |
Novel solid forms of rimonabant and synthetic processes for their preparation
|
PL2032521T3
(pl)
|
2006-06-27 |
2010-05-31 |
Sandoz Ag |
Nowy sposób wytwarzania soli
|
US7297710B1
(en)
|
2006-07-12 |
2007-11-20 |
Sanofi-Aventis |
Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
|
RU2009108280A
(ru)
|
2006-08-08 |
2010-09-20 |
Санофи-Авентис (Fr) |
Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
|
US20100076022A1
(en)
*
|
2006-09-01 |
2010-03-25 |
Hetero Drugs Limited |
Novel polymorphs of rimonabant
|
US7781593B2
(en)
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
WO2008035023A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Cipla Limited |
Polymorphs of rimonabant
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
WO2008056377A2
(en)
*
|
2006-11-06 |
2008-05-15 |
Cadila Healthcare Limited |
Polymorphic forms of rimonabant
|
FR2909090B1
(fr)
|
2006-11-23 |
2009-01-09 |
Sanofi Aventis Sa |
Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
|
WO2008064615A2
(en)
*
|
2006-12-01 |
2008-06-05 |
Zentiva, A.S. |
Crystalline and amorphous forms of rimonabant and processes for obtaining them
|
CZ300115B6
(cs)
*
|
2006-12-01 |
2009-02-11 |
Zentiva, A. S. |
Zpusob výroby N-piperidino-5-(4-chlorfenyl)-1-(2,4-dichlorfenyl)-4-methylpyrazol-3-karboxamidu (rimonabantu)
|
GB0700122D0
(en)
|
2007-01-04 |
2007-02-14 |
Prosidion Ltd |
GPCR agonists
|
BRPI0806312A2
(pt)
|
2007-01-04 |
2011-09-06 |
Prosidion Ltd |
agonistas cgpr piperidina
|
EP2377863A1
(de)
|
2007-01-04 |
2011-10-19 |
Prosidion Limited |
Piperidin-GPCR-Agonisten
|
PE20081849A1
(es)
|
2007-01-04 |
2009-01-26 |
Prosidion Ltd |
Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
|
AR064735A1
(es)
|
2007-01-04 |
2009-04-22 |
Prosidion Ltd |
Agonistas de gpcr y composicion farmaceutica en base al compuesto
|
FR2911136B1
(fr)
|
2007-01-05 |
2009-02-20 |
Sanofi Aventis Sa |
Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
|
US20080182877A1
(en)
*
|
2007-01-05 |
2008-07-31 |
Westheim Raymond J H |
Rimonabant forms and methods of making the same
|
EP1944297A1
(de)
*
|
2007-01-09 |
2008-07-16 |
Miklós Vértessy |
Festes und kristallines Rimonabant, Herstellungsverfahren dafür und pharmazeutische Zusammensetzung davon
|
EP1953144A1
(de)
|
2007-01-30 |
2008-08-06 |
Sandoz AG |
Polymorphe Formen von N-Piperidin-5-(4-chlorphenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolcarboxamid
|
US8431609B2
(en)
|
2007-02-19 |
2013-04-30 |
Darmesh Mahendrabhai Shah |
Process for preparation of pyrazole derivatives
|
WO2008101860A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Sandoz Ag |
Novel process for the preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)pyrazole-3-carboxamide
|
FR2913018A1
(fr)
*
|
2007-02-23 |
2008-08-29 |
Sanofi Aventis Sa |
Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
JP4994295B2
(ja)
*
|
2007-04-20 |
2012-08-08 |
田辺三菱製薬株式会社 |
医薬組成物
|
CN101302200B
(zh)
*
|
2007-05-09 |
2011-04-20 |
上海医药工业研究院 |
制备n-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺的方法
|
FR2919184A1
(fr)
*
|
2007-07-26 |
2009-01-30 |
Sanofi Aventis Sa |
L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
|
FR2919868A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de n,n-dimethyformamide de rimonabant, et son procede de preparation
|
FR2919865A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919866A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de methanol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919863A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919862A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919861A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919864A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919867A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
GB0720389D0
(en)
|
2007-10-18 |
2008-11-12 |
Prosidion Ltd |
G-Protein Coupled Receptor Agonists
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
WO2009109222A1
(en)
*
|
2008-03-04 |
2009-09-11 |
Maprimed, S. A. |
Process for the preparation of rimonabant
|
WO2009153804A1
(en)
*
|
2008-06-16 |
2009-12-23 |
Cadila Healthcare Limited |
Process for preparing form i of rimonabant
|
UY31968A
(es)
|
2008-07-09 |
2010-01-29 |
Sanofi Aventis |
Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
US10053444B2
(en)
|
2009-02-19 |
2018-08-21 |
University Of Connecticut |
Cannabinergic nitrate esters and related analogs
|
SG178880A1
(en)
|
2009-08-26 |
2012-04-27 |
Sanofi Sa |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8809324B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
US8846666B2
(en)
|
2011-03-08 |
2014-09-30 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8809325B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120057A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
CN102206182B
(zh)
*
|
2011-04-11 |
2013-03-13 |
中国药科大学 |
盐酸利莫那班的合成方法
|
AR087701A1
(es)
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
EP2567959B1
(de)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
|
US8962845B2
(en)
*
|
2011-09-30 |
2015-02-24 |
National Health Research Institutes |
Pyrazole compounds
|
WO2015188073A1
(en)
|
2014-06-06 |
2015-12-10 |
Research Triangle Institute |
Apelin receptor (apj) agonists and uses thereof
|
RU2021133849A
(ru)
|
2015-12-09 |
2022-03-21 |
Рисерч Трайэнгл Инститьют |
Улучшенные агонисты апелинового рецептора (apj) и их использование
|
CA3125847A1
(en)
|
2020-07-27 |
2022-01-27 |
Makscientific, Llc |
Process for making biologically active compounds and intermediates thereof
|
ES2947188T3
(es)
|
2020-11-18 |
2023-08-02 |
Fundacion Del Hospital Nac De Paraplejicos Para La Investigacion Y La Integracion Fuhnpaiin |
Uso de antagonistas y/o agonistas inversos de receptores CB1 para la preparación de medicamentos para tratar el síndrome de fatiga posviral
|